Invention Grant
- Patent Title: 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists
-
Application No.: US16765778Application Date: 2018-11-16
-
Publication No.: US11304946B2Publication Date: 2022-04-19
- Inventor: Julien Lefranc , Norbert Schmees , Ulrike Röhn , Ludwig Zorn , Judith Günther , Ilona Gutcher , Lars Röse , Benjamin Bader , Detlef Stöckigt , Michael Platten
- Applicant: Bayer Aktiengesellschaft , Bayer Pharma Aktiengesellschaft , Deutsches Krebsforschungszentrum
- Applicant Address: DE Leverkusen; DE Berlin; DE Heidelberg
- Assignee: Bayer Aktiengesellschaft,Bayer Pharma Aktiengesellschaft,Deutsches Krebsforschungszentrum
- Current Assignee: Bayer Aktiengesellschaft,Bayer Pharma Aktiengesellschaft,Deutsches Krebsforschungszentrum
- Current Assignee Address: DE Leverkusen; DE Berlin; DE Heidelberg
- Agency: Morrison & Foerster LLP
- Priority: EP17202887 20171121
- International Application: PCT/EP2018/081543 WO 20181116
- International Announcement: WO2019/101641 WO 20190531
- Main IPC: C07D401/04
- IPC: C07D401/04 ; C07D401/14 ; C07D403/04 ; C07D405/14 ; C07D409/04 ; C07D409/14 ; C07D413/04 ; A61K31/506

Abstract:
The present invention covers 2-hetarylpyrimidine-4-carboxamide compounds of general formula (I): in which X, Y, Z, R1, R2 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
Public/Granted literature
- US20200289509A1 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS Public/Granted day:2020-09-17
Information query